<SEC-DOCUMENT>0001144204-15-025916.txt : 20150429
<SEC-HEADER>0001144204-15-025916.hdr.sgml : 20150429
<ACCEPTANCE-DATETIME>20150429160031
ACCESSION NUMBER:		0001144204-15-025916
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150429
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150429
DATE AS OF CHANGE:		20150429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		15812290

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v408701_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>April 29, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 45px; width: 202px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Delaware</font></td>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">99-0370688</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">(State or other jurisdiction of incorporation)</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">(IRS Employer Identification Number)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item 7.01&#9;Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 29, 2015, Lipocine Inc. issued
a press release announcing the closing of its previously announced underwritten public offering of shares of its common stock.
A copy of the press release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>Item&nbsp;9.01 Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; padding-left: 0; text-indent: 0; padding-right: 0; width: 10%; border-bottom: Black 1pt solid"><font style="font-size: 10pt">Exhibit&nbsp;No.</font></td>
    <TD STYLE="padding-bottom: 1pt; padding-left: 0; text-indent: 0; padding-right: 0; width: 2%">&nbsp;</td>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; padding-left: 0; text-indent: 0; padding-right: 0; width: 88%"><font style="font-size: 10pt">Description</font></td></tr>
<tr>
    <TD NOWRAP STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0">&nbsp;</td></tr>
<tr>
    <TD NOWRAP STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0"><font style="font-size: 10pt">99.1</font></td>
    <TD STYLE="vertical-align: bottom; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-left: 0; text-indent: 0; padding-right: 0"><font style="font-size: 10pt">Press Release dated April&nbsp;29, 2015.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><font style="font-size: 10pt">LIPOCINE INC.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 1%; padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 45%; padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 8%; padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 1%; padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 45%; padding: 0; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="padding: 0; text-indent: 0"><font style="font-size: 10pt">Date:&nbsp;&nbsp;</font></td>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><font style="font-size: 10pt">April 29, 2015</font></td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0"><font style="font-size: 10pt">By:&nbsp;&nbsp;</font></td>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0"><font style="font-size: 10pt">/s/ Mahesh V. Patel</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font-size: 10pt">Mahesh V. Patel</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0"><font style="font-size: 10pt">President and Chief Executive Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No</B>.</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 89%; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated April&nbsp;29, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v408701_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.gif" ALT="Lipocine Inc." STYLE="height: 71px; width: 336px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE ANNOUNCES CLOSING OF $34.8 MILLION
COMMON STOCK OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>SALT LAKE CITY (April 29, 2015)
</B>&ndash; Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced the closing of an
underwritten public offering of 5,347,500 shares of its common stock at $6.50 per share. The aggregate amount of common shares
sold reflects the exercise in full by the underwriters of their option to purchase up to 697,500 additional shares of common stock
to cover over-allotments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canaccord Genuity Inc. and Ladenburg Thalmann acted as joint
book-running managers for the offering. Roth Capital Partners acted as co-manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering was made pursuant to an effective shelf registration
statement (File No. 333-199093) (including a prospectus) previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).
A final prospectus supplement describing the terms of the offering was filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the final prospectus supplement and the accompanying
prospectus relating to these securities may be obtained by contacting the Syndicate Department of Canaccord Genuity Inc., Attention:
Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts, 02110, or by telephone/email at (800) 225-6201/prospectus@canaccordgenuity.com,
or by contacting Ladenburg Thalmann &amp; Co. Inc., 570 Lexington Avenue, 11th Floor, New York, NY, 10022, or by telephone/email
at (212) 409-2000/prospectus@ladenburg.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Electronic copies of the final prospectus supplement and the
accompanying prospectus are also available free of charge on the website of the SEC at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's
lead product candidate, LPCN 1021, demonstrated positive top-line efficacy results in Phase 3 testing and is targeted for testosterone
replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product with
once daily dosing, that is currently in Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone
caproate product indicated for the prevention of recurrent preterm birth, and is currently in Phase 1 testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &ldquo;forward looking statements&rdquo;
that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements
that are not historical facts relating to clinical trials, the potential uses and benefits of Lipocine&rsquo;s product candidates,
and product development and commercialization efforts. Investors are cautioned that all such forward-looking statements involve
risks and uncertainties, including, without limitation, the risks related to market conditions for Lipocine&rsquo;s common stock,
the failure to satisfy offering conditions, the risks related to the receipt of regulatory approvals, the results of clinical trials,
patient acceptance of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s products, and other
risks detailed in Lipocine&rsquo;s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms
8-K and 10-Q and the final prospectus supplement filed with the SEC on April 24, 2015, all of which can be obtained on the SEC
website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in
this release, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President &amp; Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mb@lipocine.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (443) 213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">john.woolford@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"``M`,H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V6N0/Q*T<
M:M]CVS^7O\O[1M&S/3/7.,]ZO:UXUTC1+W['>22M-@%UB3=L!]:\ZU#0M$T[
M5HC)K:36TV)XK:WA>2X=#R`%`[],FD_(]##4*2BY8FZ36GF;'CSQ5J]EXB:R
MLKE[6")%8;`,R$C.2?3M^%=!8^-8[3P;9ZIK`;SIB458UYE()&0.W`S7(W^N
M?:;YFE-MJC(Q9-+U2R:VNT7.=D3='XZ`]:+DKX@A-G-J`-J(I-1TN[=,+Y`_
MUD+A>A3Z=J+,N-;#5(4Z4XVMNST/P[XGLO$MO))9[T>(@212##+GH?<5M5YM
MX;N-(\#VBW-]?_:)]1C22-8(V($74'!P><]Z]`L+^WU.RCN[.42P2#*L*$<V
M*HQA-RII\CV9S1\3WW_"T1X>VP_83:>?G:=^['KGI^%==7G)_P"2^#_L'?TK
MT:F<IQ\WBF_3XEMH(6'[&+(SYVG?NQZYZ?A7.^'_`!3X^\3:>U[IEOI#0+(8
MB9-RG<,9XS[BK-S_`,ES?_L%G^1JS\%_^1*F_P"OV3^2T#(;KQAXP\+A+GQ+
MHEK-I^0))[)SF//<C)_7'UKMEUS3VT,:P;J-;`Q>=YQ.!M_SV]:I>,]0LM.\
M)ZD^H,@B>W>-48\R,00%`]<UY39V]WJVC^#_``E,\D<-V7O)QG!,6]BOZ!B/
MJ*!'5KXW\3>*YI%\':1&EDC;?MM[P&^@Z?AS^%/DN?B7I(^T36^F:I$O+10\
M/CVZ?UKO[2U@L;6*VM8EB@B4(B*,!0*FH`YKPEXVL?%<<D<:/:W\'^OM)?O)
MVR/49_+O5OQ/XJT_PGIIN]0<DL=L4*??E;T`_F>U<?\`$BR'AS6=+\7Z<OE3
MQW"PW07@2J?7\`1^7I46EVR>-OBGJ-]>@36&C!8K>)N5+]CCZAC^7I0!/;ZQ
M\0_$:BYTW3['2K1N8_M62[#L>>?T%$WBCQKX4_?>)-)M[_3P?WEQ9'#(/4C_
M`!`^M>CTC(KJ5=0RL,$$9!%`'%>*_'8M?`B:_P"'9()Q)*B#S5)`SG((R""*
MQ_%OQ&U?P_XAMK>VMK>>U^RQW,R[#NP<[L'/%,^)?AK3/#G@*[&DV_V=;B\B
M>1`[%<\]`3Q^'M2F".Y^,&FP3H)(I='V.C=&!1@0:`/1],U&VU?38+ZSD$EO
M.@=&]O?W'2LKQQK5SX>\)7NI60C,\`7:)!E>6`Y'XUR/AV>7X>^,7\-7KL='
MU!C)I\SGA&/\)/Z'WP>];WQ5_P"2=:I]$_\`0UH`9?WWC*ZM-,N=`@TUXI[.
M.68W!((D89..>G-4_/\`B;_SZZ'_`-]'_&NBT?5+&Q\.Z2EY>VUN[643!995
M4D;!S@FK?_"0Z/\`]!:P_P#`E/\`&@#G[&7QVUM=?;[?2UE`3R/).<\G=G)^
MGZUUT>[RU\P`/@;@.F>]+'(DL:R1NKHPRK*<@CU!IU`'G/BOP!>ZEKTE[83V
M^RY(++,Q4JV,<<<CBL:6]NX[&*VTNYN8K.%QI]M]F58[C4Y]QWX<@E(ER>:B
M^(":B?%DQN!.8SM^S;0=NW`^[COG/O5O6K+49;5Y=0@F:XM_#,I\PJ<I(9/7
M^]M'/>DMSU<9[3ZM2YIIKL>C:3H-GI-A%;Q1N_EL9`T\AE<.>IW-SFN+\::1
M!H=U#<Z;;1+]LANK2.UB)#S7$^T`@=,<$GTQ6C8>.OLZ?9)M.N+B588I;06A
M$INX"HS(N<9*G.1UKG-9\3KK^KAUO_L9@W1VT-KILLFH!6`#?>&$STR*9Y0R
M[\,S>(9471IHYY--AAL;HL2L?F(@!V-T8#H?0UZ%X4T1_#^@PV4L@DE!9W*]
M,DYP/:O+?$]O/I\>FVUO:W=CIBVRF""4%6#'.\OCJY/)_"O3/`[7S^%+0ZCY
MGF\[3)]XIGY<_A26YZV)57ZE3YIIQ[=3F3_R7P?]@[^E>C5YIK]OKFF?%$Z[
MIVAW&HP"S6$;&"@DYSS[5H'QKXJQ_P`B-=_^!"_X4SR2C<_\ES?_`+!9_D:L
M?!E0_@B=6Z&]E!_[Y6DBTS5;KXH1:Q+ITT-M+I05V."$D*\IGU!XJ[\*M)OM
M&\*2VVI6LEM,;MW"2==I"X/Z4#$7X5Z-)JIO+Z>^OE#[H[>YG+H@]/4CZFLW
MQG(/#GQ'\.:Y*`E@8S9R,!A8^OY##9_`UZ16;K^A6?B/2)M/U!-T4G((^\C#
MHP/J*!&B"&4%2"#R".]+7F=G_P`)MX$46:60\0:4AQ"T9Q*B^F.OX8(]ZLR^
M./%FHKY.D>#KJWF;CS;PD(I]>0H_6@!GQ:N_MT&E>'+7Y[V_ND;8.JH.,G\3
M^AJ'P?*GAOXFZ]HESB,7Q6>V+?QXR<#\"?\`ODUL>$/!%QIVI2Z[XANA?:W,
M,;NJP@]E]\<>F.!5KQKX)C\50PW%O.;35+4YM[E>W?!QSC/.1TH`ZJBO.+7Q
M7XUT%1;:WX9FU/8,"YLSG>/4X!'Z"FW6K>.?%RFST[1VT&UDXDN;ECY@7OC@
M'\A^(H`D^+U]:W?@6=+:YAF:*ZC$BQR!BAYZXZ=#5>'_`)+1I/\`V"1_Z"U)
MXI\`'2_AN=)T&UEO+M[F.69U`WRD9RQ]AZ5?BT741\5=-U$V<HLH]-$3S8&U
M7VGCZT`;WC7PM%XLT"2T.$NH_P!Y;2_W''3GT/0UP.H^*)=;^%&LZ?J8*:QI
MNR*Y1_O,!(H#?T/O]:]?KS#XH^!;O49/[6T&!Y+J5?)NX(C@RKV;WQ@9_#TH
M`Z*#P=H?B/0]'N=6L%N98["*-6+L,+M!QP1W-'_"K?"/_0'C_P"_K_\`Q513
MZUKN@:;I-G8^&KC40+&+S724)Y;@8*D8Z\56_P"$U\4_]"-=_P#@0O\`A0!V
MMI:Q65I#;6Z;(84$<:@YVJ!@"IJY[PUKVKZO/.FJZ!-I21J"CR2A_,))R.!V
MKH:`&.#L)4`L!E0?6O$(=;UU_$BL;BY:]:?:T!)()S@J4Z8[8KW*HOLT`G\\
M0Q^=T\S:-WY]:35SMPF*CAU+FAS71Y/KXT;0;F;17MI[V&&<W%OMF,+6&\9*
M1N.3Z\\<U-KE[?V7A*RN-/U;4+FSO9"3-<$>;$`,",NH!(SNZ^E=-XE\`6VN
MZI]N2[>VEDPL@"!@V.,]1@XKHM.T>TT[2(M-CC$EO$NW$@#;NY)_&C4V57"T
MHTYPC>2W3_K[CD?AC?W^H65Y'>N]Q;1,OE22G<0W.0">O;\Z[RF0PQ6\8CAC
M2-!T5%``_`5)31QXBJJU5S2LGT/!?BGJ%Y;^/KR."\N8D$46%25E`^4=@:YZ
M_GO[.TTV9=3OV-W;F9@9VPIWLN!S_LU[1XB^&.E^)=:EU.[NKR.:154K$RA?
ME&!U!K-;X+:*P4-J&I$*,*#(IP/0?+08G!>'=*N]<TLW+:W?Q2K.Z&(3M\T:
MQ[R5YZ@D<>F?2N<M=2U&YGAB_M.ZC\UU7<UP^%R<9//09KV)/@UI$8`CU+5$
M`)(VRJ,$C!_A].*9_P`*3T+_`)_=0_[[3_XF@#S?Q$MSI,OEV]YKZ%)7A9KQ
MBBR%?XD(/0^GICFFZ$+O48+VYN+[69DM?+'D64K-*Y<D9Y/"C'/U`KTZ;X.:
M3<;//U35I=B[4\R96VCT&1P*(/@WI-K)YEOJ>JPR8QOCF53CZ@4`>3:Q/J.D
MZS=V(U:\E%O*4$@G<9Q^/!]??-:FKV=UIWA;2]576-2,MZ%S&UP2O().,'(Q
M@=>N>.E>@_\`"E-#_P"?[4?^^T_^)I[?!K2&C$;:EJAC&,(95(XZ<;:`/-O"
M\<FLR7QU+7+^TM[2!93*+@X&7"\Y/OT')Z5B?VIJ!DVC4[O!;`8W#@=>O6O8
MU^"^BJK*NH:D%<88"10&'7GY>:;_`,*3T+_G]U#_`+[3_P")H`X'7]/N](LI
MY8=3UE7M;E;9VN9&5+@E2=\6#RO'OP0<U!X1MKSQ)J\EI/JNHHJPF0&.Y().
MY1U8X_BS^&*])E^#FDSI&DVJ:K(D0VQJ\RL$'H`1Q38_@QHT1S%J.IH3W650
M?7LOM0!X]<:G?0W$R1ZI>O&CLJOYSC<`>#C/&?2MS7=,U;1-'TZ];5;QWN%Q
M<1_:&S`Y&Y5.#D94]^X->B-\%=$9BS7^HEB<DEU))_[YIS?!K1WW[]2U1O,(
M9\RJ=Q'0GY>30!Y=I$T][8:M-<ZGJ@>RMO/C$5P<,=P7#9/JPZ>AJ/0);[5]
M?L-/EU2_1+F98V9)VR`?3FO5%^"^BH&"ZAJ2AQA@)%&X>A^7FA/@OHL3J\>H
M:FCJ<JRR*"#[';0!Y-JMY>V6J7-M#J5^8XGVJ6N6)_$\?RK7NK&[B\+QZFFJ
M:N)?(BG<R2MY+[W9-B-G.X8SCGC/2O0I/@QHTTC23:CJ<DC'+.\BDGZDK3G^
M#>DR0I$^IZJT4?W$:92J_08P*`,'X+7MU=:WJ:W%S/,%MT($DC,!\WN:]@KE
=_"G@+3_"%W<7%C<7,K3H(V$S*0`#GC`%=10(_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EA4`%'`/4``'5W>?#!ND-%1[&RL]A<8.7EYA@9&^2-B,+"Q#8X.OOL
MZ=/3U-`L2)&3E(.$AJ&BHR@J+%Q>8$]25-,^4/;=V&EK;.JFH///R=9.6-YU
M<]QI:N>9E.VSK>*!?B\N+&9F9,C'Q_'Q\9Z=G:RKJW1T<DM*2%E85CT\.H*"
M@./CX[JYN0```\X10?___P``````````````````````````````````````
M`````````````````````````````````"'_"UA-4"!$871A6$U0_S]X<&%C
M:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B
M/SX@/'@Z>&UP;71A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K
M/2)!9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O
M,3(M,3<Z,S(Z,#`@("`@("`@("(^/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P
M.B\O=W=W+G<N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F
M.D1E<V-R:7!T:6]N(')F.F%B;W5T/2(B(/]X;6QN<SIX;7`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S4@5VEN9&]W<R(@>&UP33I)
M;G-T86YC94E$/2)X;7`N:6ED.D(T,T8U.#DY0C,U03$Q13!"144P13@U-C4V
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M/B`\+W)D9CI21$8^(#PO>#IX;7!M971A(#P_>'!A8VME="!E;F0](G(B_S\^
M`?_^_?S[^OGX]_;U]//R\?#O[NWLZ^KIZ.?FY>3CXN'@W][=W-O:V=C7U=33
MTM'0S\[-S,O*R<C'QL7$P\+!P+^^O;R[NKFXM[:UM+.RL;"OKJVLJZJIJ*>F
MI:2CHJ&@GYZ=G)N:F9B7EI64DY*1D(^.C8R+BHF(AX:%A(."@8!_?GU\>WIY
M>'=V=71S<G%P;VYM;&MJ:6AG9F5D8V)A8%]>75Q;6EE85U955%-245!/3DU,
M2TI)2$=&141#0D%`/SX]/#LZ.3@W-C4T,S(Q,"\N+2PK*BDH)R8E)",B(2`?
M'AT<&QH9&!<6%103$A$0#PX-#`L*"0@'!@4$`P,"`0``(?\+35-/1D9)0T4Y
M+C`8````#&US3U!-4T]&1DE#13DN,$!I2Y0J`"'_"TU33T9&24-%.2XP&```
M``QC;5!02D-M<#`W,3(````#2`!SO``L`````%`!1P``!O_`EG!(+!J/1$5@
MJ4`ZG]"H=$JM6J_8K';+[7J_1DJ&129G*."T>LUNN]]P*`@4<E\8Y3SC$N_[
MJ0@-``*$A1$``P5Q@8.%A!(`#XI_E%@B)R8?'BAU:@IX>7IH?P(KIBL#60.G
M*P!#`*RQLBL&`A(."%X/$0:SL@(.DVD(%1"^L0D."U*PIZY"I;&Y7+%#J\?8
MOJE"'R0C<R&7G6`=H>89E-&FVU?7IL\MS=F^$,%9#<;SLA'+NNKZIR2P0R*O
MU9!_IA)TJ2;$'<!LVT9\:.'A0XF)(E"H`66N#(-TK`96<0BOX$-6$!Y8>9#O
M9*P*PK`@0.AR182810K"HVEP"\/_%@YKRMIF0@7%%B$\(/4P#LJ%#!/(8-C0
MA`B%CN;X%`F0@0`!#52__!-)A>0KH;(J3"D@(5LM`0G<JL1B4M9;GJP,S#6B
M\Z"O:5E^!D5[:IM2BB)(3&SQ`824`QTG:!42`&NH`$D(F&/`P<M85:Q*LHHP
MH+3ITP\`1&@Y.@J"7K-N`1Y2X$$Q7VJK%,";`)&1`@,`Q)T5X4A?:+X4:OD)
M_+3SY]"=3SKL042)%-P<0X&,E<&H%@HLY_FN`(/ESEP^8S$KY'B4`30=/&D`
M&Z6]]Q%F"<#I9,'P6!',UA\OO^#D'EX]8?%3&]X<)5$+*9P0Q57B$4!$5.)-
M0,08EC%0_Y46ZK43VEG.5$%?7OT8T8!=\`!"4P+\_5;?*0*D.,4"^2$3TX&L
M($36%`NR`4()20E1`@@DB!!%.>*Q\)T%31XP!(7B;9!>2*"5V-Z(5;S6FA$(
MR)*`C58X\`L4!?QWBGRJS+B"<EMJV<)8:D(08Q1!LF'="'6`\,%B4&C6I`5$
MF(<5!D1`V:2%6X1H!7OQ<%F%F:S@M(";Q7'A)2NY(=%67@)>D2:`)+[C5V%A
M<JH@*WT@Z8$')HPP19-D2#F$`H*&@L&'+7"7X96%96EJG,-:\0^;IYZ2:1>;
MGK)7$92>8D"H6(S*REP\!FO2CU#D6<D3&(IG:Z*Y8D!H"X#Y:O\9HHUBN9ZD
M[IG(B@1$1&O*LEXT2PM_EX(*AK6F0$!L@NK5>:<3WGZ+A`:T8G8+F40L4,HV
M'-"J`;#K")M@O%04P`J<!<PHP!I!=3I$CLZJD>HI#40JIWKZFBQ%P@H;H:AE
M&JXL00/\?6HG>!QA=2Z([HHH)\=4S%@J+1![89*-"[SD1[89"V$O*E707',1
MN7;4606R["Q,OS8)H:XY&F*,];M'2VHLJRV$S`JR:["&+\K[3BVIH__\#"3<
M6T-1'E96QNV`FLI.$^U<'&XV&='!LETLTE.P)L2*IPCL!N:F&#")W&O^0?7:
M0I!MBLQ/:!WXK1T$/0%Z$1\>B]^?>F[_MCD$?-=NY$9/[G;6T@JA)MULL-9R
M"YS30LGH(EW];.J`KRYX`!8$\/@1"]QF"KUQPS:R$`I8<,#XU^]>=>\;_S[%
M`SW&'<O!7]C+/=ZHO\&\$?_8CF?T@7/E%0$=T-T1B)$``T1`$D7@')O89PKB
M(2$`XSM`^:#@J)'`2WU2H%\+&+B].$0M>"U@#;7<<+\BF&X%W.L6_Q2F`(:9
M8UQ$V`5K:*2,DYUB&CDR0#^"XYLA<"!<4ID@$BI8E@O*J8BLR$5!',@&-2W`
M8R`4W=Z*5J]8/.\(JNN#H3K2`2$4H`$2<!,]*H``:_VL`/EX1C/@<3-S#(V"
M5+1@VXXH!32B_P0YO'L#WDHSKTJ4$']Y@5\+L@B'LYD#,S0QX`,&4`'$F:(!
MF^+>&N-TO,IT2(!#C",2?4='*/C'BL);81N6R,$$Z>UEFO3BC%*(A)\L``"P
MC*4L9TE+`#1-"D'KR,6B!8$*7'$!#OB4J13HLF>`;6U=ZP@ZHD#$*4"*<D<H
M``#<E$)">B%YL,2@_::8QR*4<@57)()@"$.Z*ER`5A_Q#QE5)`$!'&^#$;B)
M$%#VRF%%(Q7A:=)'F)E**3Q3FZ4;0#!G`:,A?,P/)%FB'[EYOB,(,V^M!-Q@
M3L(M*%BR24C817V^%\WA\+$G]VS!1<4CA6;ZTXC%(H(CQ123@_8AH?\`'25#
MRRFC/D;T%-8@9T6?,%++>)-`4G,"`B0@`>!T<$X9ZRE62MK/]Z#4E+19J;)P
M8LTNZ,1>+>K#'S,*2BP";B:."*M8Q3I"*%`)9T,XT>S6Z4Q3?"^D9_4I/[NY
MR?1UTHLK%<"/U'1*4RQ25<N;Z4Z%\%`=>A6G@=LB5KH(E+66U0G7>&O5@*A+
MIM*UK7-,:1$`E@"V'L&D:AC+RE;`T;X2K*FT$=EA3;$ZI>JA":!3I!8BB\=M
MM+$CF)EK0^7(2<UN=@"/71H3UZ"T058JL*B\K!&^Z<"JNN&V'M%*-*85MU*\
M$XDC6QD[7*C,*8`6"O^\*Q9*R<HV.$0Y:KK_;ARV^@2\&5:<HOS6#T-!`*W(
M8R['+.T44G63X<`)/(W+`V,MN]NZBD:\HHK%+<&@P18<\ZBFW0EJB6!'&A7!
MN7#@0`0GXX[<N".KS@S&@Z=A&T7XSRL!K,)WGQ!>WVKAH2!.`^A,,8W1KF#!
M:V`OBV-!-PQ7`G3*J;!^'Z6E?B4@N+JEJ8&7%N-[!)*$=QR"W:28W`(_X<%,
M,VA\I1?*++>@=CA&D_?PVCE!)GFPD'UJD[,PH_IYX837O1J2OZ#C)U38K5I&
M+)?YDK(-LFP+8)ZG<E4\X31G%JI<V!8;'JJYU+I4#0Z092KJO..Y"<'';E""
M];S8EMR0K;Q6X-SQ_SBW9D(/&KQJ5@-K]`>&JZG79<I20_*P1NDK^PO3:[A`
MUQA@*V1-5YK`P`)LN+<ICEJ``'B80`9RZ]U"(Z'%B.9"4`KZA5D/60@S?+46
M;"Q)P8J*-0K!=1J@*Y4/<2X5>@:>[<RHB,&98\!GUMB!7<P%++_)S%)XP(S>
M:X3!:+L=^YY$K9]@8Y.TMD(DRE2ZJ9":7"Q`F+EP-Q>;?>I*]S;:7`!80N8\
M'UG\>V"GX\*L23?P)]1ERWY(IAOC](R%=ZP!PQ,"DRS#[">LV-`7+[46[MRY
MX4:!+;+0>0OPYM8P(P'HL;ANR9\@U14$[IQ-NE@Q+\U:W8`Q;$.P&(&5C/_9
MG+<!`3,D+9H3*$9\M9=%^$ZK&-6[=*$>(W#D#L4^)VE<I[?@B5!XP$-/D8PA
MN%;N6Q_[$:`M])WG]>-#`&;8,8X$HG?.EIYTP.)?W78GG-SN-3-D1^+$)IRR
MC[H(0T8-B?#W4&S]$+5,/2P;DFHW(-TND`"N%P>0&JGJY0J7?Y,O$]&0VOO"
M`#^JO!-6FGC5&U_U1F]!Q9J4MF9L`Z?-\!NZ8@*;9$`L%Z7/P]:%POI#%YX+
M^B8GC9(_^,77I*@$\?86;%SUQHK?V7'M+E+7!AMT!40(Q]S9,H!)IB^&T0`M
M$'_FP"YP1$[=YW5Q4`".=Q(0@'AU-$V$D1(FIW[_6U`7.?5^%3<$*G<9M85'
M5A,Z")$,@`%,B*,2&Y@'A5.`A'&`=D5O;)`]8I0-">"`N@$`YG<,,Q@%PL=T
MXX2!5G8$%)!+>;!,\[<-(35T-X0/LP`!J[&$*I%]$\`K3E`!8U6%52@$8$4(
M[]0`CD"#:Z!1,NA9:F`;-Y@08C@?73@$5%@('.=)834$66B%<DA65'`'\M>!
M7Q8PBF`MMD.",@@`LQ%W>[!G>[8`/"1+#2!X7@`<D29+#L![A!B)2*``!Q`N
M&E!S<5,:DT`VF5)L%`9&J]0`MQ0`E)4!4BB)J)B*JKB*4K`XEQ,0H9(:X70$
M%R`^'(!)K)B+NKB+WV(!_]RE`4/S:_B'$F=X*[[H%1GP1EN0?;32C,[XC-`8
MC=(XC=18C=9XC=4(0UJ`*QU!`+`U9EU&C+-Q`93%`A@@1%7`C-BXCNS8CN[X
MCO`8C^+B!2=HCD+`0<@"AK.C$G;8$=[!!>HHCP(YD`19D`9IC=J(!7%7!K:2
M0V2R"]+0`N68!XRB!0%YD!B9D1JYD>Z8D%<PD7F0-G9T>[]Q=0*SD&6`CE*@
MCA.`;,WH%65``(JE3QEP`-SEC`Q0DQH@A);Q/_4H=_\SD\RGD]#HD]'8DCCI
MDR`9DD9)*RWI%3SY0ER03TTR"@-P9$*@80=@`;I3`+D08%CAD52@CE+RDV4@
M!/\N)%+.:(JW(I18P9;@XY:;-R5+&9.)XHPP1`%R:0Y$T(_-B`9F2085V2NT
M`D/-"$,6$)4,"9#-B(D;D$MPJ8&%N8R3&9@L(`04HI:T8B&42`"$H@!U2087
MTYF?&9ID$(`'T!DH*9@B=0!-L)=E,)H'X)G@89J720$'@!D;X(R,LGS,=P!H
M,)N3*3Z:)Y46$!:K*99UV(R/`Y9E,`&Z$YC*N9*5V8Q#4`Z:V21\4"X$8)K;
M609=M)JG:4G9V9.$:26!B09;)"6[22MJJ2$7^9D2Z8R8@9<M8)FU<I\L\(]U
M.9U3H)ADL$]"T)Z'LB&TDH)80);ZZ9[6\PGEZ5-0%XW_+1"AXVF=%Z`!JKF9
M`9A;IEF>'Q&0$XJA+4"@OR(&A-F8+6"?65>=+%"6\\@%SAD*1/@)@^)WM(*+
M8\FB&!4`%F(E("J`[DFA'VJ=0^"7Y@D^,<J7%`J?1"H$1FH94J(`?$"535*?
MASFA2W"E@N*B4-H%--H=W^&;EB%U0O"3\):@.DI2E8$>`8D9C8,!+JF=+<!=
M4B*>MZD`H/F2)^J,@%D&A$*B/H4&7WJC19"D'&B?^-FB^NDA\]FE7?"D`?HX
MQ4F122"7N\*84;*@.\H":1.0C+(!(IJG43>@P%B;UAD`742AYCFIE:4`H-H9
M@ZJF4A*0Z&!)%J*J6&&EPSD^_U=J`1;0!(`JE5Y``3?)`AH@0*S*FDE0K"S0
M`:=X!0IJF9HYJVOY(7I9K5,"F]I7&;JIH<EZ#E:AK6=9&7SPK9C!7>K9,"EZ
MI2N:J4,0K,+Z!9H6`,\*K_0%A!LP/ESY!2P9IXMB*`P@D\_(`!H@G-!(L`;+
MF^81L($9L+8I=S69J"P@L"TIKC#YG-U)*W#JC$]YL<SW/RKJ!T"*@G]PD1QY
MLBB;LBJ;GY3`K*]5LBL;LS([LQSIGVL0JZ&@C'!@LC3;LS[[LY-9"1<@E`R@
MLW`PKTN0M$J[M$S;M$[[M%`;M5([M51;M59[M5B;M5J[M4Z+HW'@BQ,0L,#)
,BV1;M@5F6S-!```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
